Sun Pharmaceutical Industries (SUNPHARMA) Stock Overview
A generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
SUNPHARMA Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.676.1% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeSun Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,872.70 |
| 52 Week High | ₹1,885.80 |
| 52 Week Low | ₹1,548.00 |
| Beta | 0.097 |
| 1 Month Change | 13.16% |
| 3 Month Change | 9.66% |
| 1 Year Change | 11.06% |
| 3 Year Change | 96.51% |
| 5 Year Change | 172.53% |
| Change since IPO | 92,019.72% |
Recent News & Updates
Narrative Update • Apr 26
SUNPHARMA: Obesity And Diabetes Launches Will Drive A Constructive Outlook
Analysts have nudged their price target on Sun Pharmaceutical Industries slightly higher to ₹1,958.92 from ₹1,956.28, citing updated assumptions around revenue growth, profit margins and future P/E that leave their overall valuation framework largely intact. What's in the News The US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026.Narrative Update • Apr 11
SUNPHARMA: Obesity And Diabetes Launches Will Support A Constructive Outlook
Analysts have trimmed their price target for Sun Pharmaceutical Industries by about ₹5 to reflect slightly adjusted assumptions on fair value, revenue, profit margins, and future P/E expectations. What's in the News US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026, following prior approvals for multiple psoriasis indications and broad global authorizations (Product related announcement).Narrative Update • Mar 28
SUNPHARMA: Obesity And Diabetes Launches And Disciplined Mergers Will Guide Balanced Outlook
Analysts have trimmed their price target for Sun Pharmaceutical Industries slightly to around ₹1,961 from about ₹1,976, reflecting updated assumptions that keep revenue growth, profit margin and future P/E expectations broadly similar to prior estimates. What's in the News Launch of semaglutide injections Noveltreat and Sematrinity in India for chronic weight management and type 2 diabetes, with weekly therapy costs reported in the INR 750 to INR 2,000 range to support affordability across multiple dose strengths (Key Developments).Narrative Update • Mar 12
SUNPHARMA: Obesity And Diabetes Pipeline And Mergers Will Shape Balanced Outlook
Analysts have nudged their implied fair value for Sun Pharmaceutical Industries slightly higher from ₹1,967.71 to ₹1,976.35, reflecting small adjustments to revenue growth, profit margin assumptions and the future P/E multiple in their models. What's in the News Sun Pharma received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection for chronic weight management in adults, to be launched as Noveltreat after patent expiry in India, with multiple dose strengths offered via a prefilled pen (Key Developments).Recent updates
Narrative Update • Apr 26
SUNPHARMA: Obesity And Diabetes Launches Will Drive A Constructive Outlook
Analysts have nudged their price target on Sun Pharmaceutical Industries slightly higher to ₹1,958.92 from ₹1,956.28, citing updated assumptions around revenue growth, profit margins and future P/E that leave their overall valuation framework largely intact. What's in the News The US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026.Narrative Update • Apr 11
SUNPHARMA: Obesity And Diabetes Launches Will Support A Constructive Outlook
Analysts have trimmed their price target for Sun Pharmaceutical Industries by about ₹5 to reflect slightly adjusted assumptions on fair value, revenue, profit margins, and future P/E expectations. What's in the News US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026, following prior approvals for multiple psoriasis indications and broad global authorizations (Product related announcement).Narrative Update • Mar 28
SUNPHARMA: Obesity And Diabetes Launches And Disciplined Mergers Will Guide Balanced Outlook
Analysts have trimmed their price target for Sun Pharmaceutical Industries slightly to around ₹1,961 from about ₹1,976, reflecting updated assumptions that keep revenue growth, profit margin and future P/E expectations broadly similar to prior estimates. What's in the News Launch of semaglutide injections Noveltreat and Sematrinity in India for chronic weight management and type 2 diabetes, with weekly therapy costs reported in the INR 750 to INR 2,000 range to support affordability across multiple dose strengths (Key Developments).Narrative Update • Mar 12
SUNPHARMA: Obesity And Diabetes Pipeline And Mergers Will Shape Balanced Outlook
Analysts have nudged their implied fair value for Sun Pharmaceutical Industries slightly higher from ₹1,967.71 to ₹1,976.35, reflecting small adjustments to revenue growth, profit margin assumptions and the future P/E multiple in their models. What's in the News Sun Pharma received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection for chronic weight management in adults, to be launched as Noveltreat after patent expiry in India, with multiple dose strengths offered via a prefilled pen (Key Developments).Narrative Update • Feb 25
SUNPHARMA: Obesity And Diabetes Franchise Will Support Long Term Upside
Analysts have made a minor upward adjustment to their fair value estimate for Sun Pharmaceutical Industries to ₹1,967.71 from ₹1,963.26, reflecting slightly higher assumptions for revenue, profit margins and future P/E. What's in the News Sun Pharma is evaluating acquisitions that it believes could strengthen its long term capabilities, with management indicating it is open to using debt financing if the target, cash flow profile and repayment visibility are acceptable, while emphasizing that media reports about specific targets are speculative and that any deals would follow a disciplined approach to mergers and acquisitions.Narrative Update • Feb 11
SUNPHARMA: Obesity And Diabetes Pipeline Will Drive Long Term Upside
Analysts have trimmed their price target on Sun Pharmaceutical Industries by around ₹2. This reflects updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with their earlier view.Analysis Article • Feb 05
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹11.00
Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) will increase its dividend on the 16th of February to ₹11.00...Analysis Article • Feb 03
Results: Sun Pharmaceutical Industries Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) just released its third-quarter report and things are looking...Analysis Article • Jan 30
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Share Price Not Quite Adding Up
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 23x, you may consider Sun...Narrative Update • Jan 28
SUNPHARMA: Obesity Treatments And Organon Bid Will Drive Long Term Upside
Analysts have nudged their price target for Sun Pharmaceutical Industries slightly higher to ₹1,965.29 from ₹1,955.16, reflecting small adjustments in projected revenue growth and future P/E assumptions, while the discount rate and profit margin outlook remain broadly unchanged. What's in the News Sun Pharmaceutical Industries received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection for chronic weight management.Narrative Update • Jan 12
SUNPHARMA: Obesity And Psoriasis Pipeline Will Drive Long Term Upside
Analysts have nudged their fair value estimate for Sun Pharmaceutical Industries slightly higher to ₹1,955.16 from ₹1,950.68, reflecting updated assumptions around revenue growth, profit margins and the future P/E multiple. What's in the News Sun Pharma launched ILUMYA (tildrakizumab) in India for adults with moderate to severe plaque psoriasis, supported by an Indian clinical study where up to 93.9% of patients reached 75% skin clearance by week 28 and up to 78.1% reached 90% skin clearance, with the treatment reported as well tolerated.Narrative Update • Dec 25
SUNPHARMA: ESG Power Shift And Obesity Pipeline Will Drive Bullish Long Term Outlook
Analysts have reiterated their price target on Sun Pharmaceutical Industries at ₹1,950.68 per share, citing broadly unchanged assumptions around discount rates, long term revenue growth, profit margins, and future valuation multiples. What's in the News The U.S. FDA has approved an updated label for Sun Pharma's immunotherapy UNLOXCYT for advanced cutaneous squamous cell carcinoma, incorporating long term pivotal trial data that showed durable responses and no treatment related deaths, with commercial launch targeted for early 2026 (Key Developments).Narrative Update • Dec 11
SUNPHARMA: New Therapies And ESG Initiatives Will Shape Balanced Long Term Outlook
Analysts have nudged their price target for Sun Pharmaceutical Industries slightly higher to ₹1,950.68, reflecting modestly stronger long term revenue growth expectations, while largely unchanged assumptions for margins, discount rate, and future valuation multiples. What's in the News FDA approves an updated label for Sun Pharma's immunotherapy UNLOXCYT for advanced cutaneous squamous cell carcinoma, incorporating long term pivotal trial data showing durable responses and supporting a planned US commercial launch in early 2026 (FDA filing) UNLOXCYT trial results highlight rapid and sustained responses with a favorable safety profile, reinforcing Sun Pharma's strategy to expand its differentiated cutaneous oncology portfolio and pursue guideline inclusion in future NCCN updates (Company announcement) Sun Pharma reports positive Phase 1b/2a data for GL0034, a novel long acting GLP 1 receptor agonist, showing significant weight loss, liver fat reduction, and metabolic improvements in post menopausal women with obesity and metabolic liver disease, with tolerable side effects (AHA 2025 presentation) AstraZeneca Pharma India and Sun Pharma enter an exclusive second brand partnership for hyperkalemia drug Sodium Zirconium Cyclosilicate in India, with AstraZeneca marketing it as Lokelma and Sun as Gimliand to expand access across the country (Company announcement) Board approves a proposal to amend Sun Pharma's Memorandum of Association to enable setting up captive solar, renewable, and other power plants, including sale of surplus power to the grid, in line with long term ESG and sustainability goals, subject to shareholder and regulatory approvals (Board resolution) Valuation Changes Fair Value: Unchanged at approximately ₹1,950.68 per share, reflecting stable overall valuation assumptions.Narrative Update • Nov 27
SUNPHARMA: Revenue Projections And New Approvals To Shape Outlook In 2024
Analysts have raised their price target for Sun Pharmaceutical Industries from ₹1,930 to ₹1,951, citing improved revenue growth projections as well as slight adjustments to profitability and valuation metrics. What's in the News The U.S. FDA approved an updated label for Sun Pharma's UNLOXCYT (cosibelimab-ipdl) for metastatic and locally advanced cutaneous squamous cell carcinoma (CSCC).Analysis Article • Nov 07
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Could Easily Take On More Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Oct 13
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
With a price-to-earnings (or "P/E") ratio of 38.7x Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) may be...Narrative Update • Sep 04
Specialty Therapies And Emerging Markets Will Unlock Future Potential
With both the Future P/E (41.57x) and Net Profit Margin (22.70%) remaining essentially unchanged, analysts have left their consensus price target for Sun Pharmaceutical Industries steady at ₹1930. What's in the News Sun Pharma announced positive top-line results from two Phase 3 studies (INSPIRE-1 & INSPIRE-2) of ILUMYA (tildrakizumab) for active psoriatic arthritis, meeting primary endpoints with no new safety signals.Analysis Article • Aug 04
Earnings Miss: Sun Pharmaceutical Industries Limited Missed EPS By 22% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) filed its first-quarter...Analysis Article • Jun 27
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Will Pay A Dividend Of ₹5.50
The board of Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) has announced that it will pay a dividend of ₹5.50...Analysis Article • Jun 26
What Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Not Telling You
With a price-to-earnings (or "P/E") ratio of 36.7x Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) may be...Analysis Article • May 25
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
The board of Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) has announced that it will pay a dividend of ₹5.50...Analysis Article • May 15
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
New Narrative • Nov 07
Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges
U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.Shareholder Returns
| SUNPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.7% | 4.1% | 2.1% |
| 1Y | 11.1% | 12.1% | 8.1% |
Return vs Industry: SUNPHARMA underperformed the Indian Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: SUNPHARMA exceeded the Indian Market which returned 8.1% over the past year.
Price Volatility
| SUNPHARMA volatility | |
|---|---|
| SUNPHARMA Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: SUNPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SUNPHARMA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 43,000 | Kirti Ganorkar | sunpharma.com |
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle.
Sun Pharmaceutical Industries Limited Fundamentals Summary
| SUNPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹4.49t |
| Earnings (TTM) | ₹109.15b |
| Revenue (TTM) | ₹568.09b |
41.2x
P/E Ratio7.9x
P/S RatioIs SUNPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUNPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹568.09b |
| Cost of Revenue | ₹121.91b |
| Gross Profit | ₹446.18b |
| Other Expenses | ₹337.03b |
| Earnings | ₹109.15b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 22, 2026
| Earnings per share (EPS) | 45.49 |
| Gross Margin | 78.54% |
| Net Profit Margin | 19.21% |
| Debt/Equity Ratio | 6.7% |
How did SUNPHARMA perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 17:20 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sun Pharmaceutical Industries Limited is covered by 74 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Parin Tanna | 360 ONE Capital Market Private Limited |
| Prashant Nair | Ambit Capital |